who note 'relenza'? it is a very good article; every reader will come away knowing tamiflu and the new wonderboy biocryst. relenza is glossed over and biota unheard of!
what is bta management going to do about this publicity gap? are the shareholders expected to twiddle their thumbs and exercise more patience?
